MICROVIABLE THERAPEUTICS
Mission & Vision
Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable’s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients’ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.
NEWS
You can follow the latest news of MicroViable in this section
The Microbiota and Cancer: Exploring the Link between Microbial Composition and Oncogenesis
The microbiota plays a crucial role in human health, directly influencing digestive functions, protection against [...]
Abelardo Margolles, co-founder and scientific advisor of Microviable among the Highly Cited Researchers 2023.
Clarivate a research organization and global expert in data insights and collection, recognizes the true [...]
Microviable Therapeutics will be presenting at Microbiome Connect USA
Microviable Therapeutics will participate in Microbiome Connect USA that will take place from November 14th [...]
CONTACT

Get in touch with us for any questions using the following contact form.